Everolimus-induced epithelial to mesenchymal transition in immortalized human renal proximal tubular epithelial cells: Key role of heparanase

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Masola, Valentina ^a   Zaza, Gianluigi ^a   Granata, Simona ^a   Gambaro, Giovanni ^b   Onisto, Maurizio ^c   Lupo, Antonio ^a  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Epithelial mesenchymal transition; Everolimus; Heparanase; mTOR; Tubular cells

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; FIBRONECTIN; GELATINASE B; HEPARANASE; PROTEIN KINASE B; TRANSFORMING GROWTH FACTOR BETA2; VIMENTIN;

ARTICLE; CELL MOTILITY; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY FIBROSIS; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

ACTINS; CELL LINE, TRANSFORMED; EPITHELIAL-MESENCHYMAL TRANSITION; FIBRONECTINS; GENE EXPRESSION; GLUCURONIDASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TUBULES, PROXIMAL; MATRIX METALLOPROTEINASE 9; SIROLIMUS; VIMENTIN;

EID: 84887730300     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-292     Document Type: Article

References (69)

1. Geissler EK, Schlitt HJ, Thomas G. mTOR, cancer, and transplantation. Am J Transplant 2008, 8(11):2212-2218.
2. Chapman JR, Valantine H, Albanell J, Arns WA, Campistol JM, Eisen H, Frigerio M, Lehmkuhl H, Marcen R, Morris R, Nashan B, Pascual J, Pohanka E, Segovia J, Zuckermann A. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transplant Proc 2007, 39(10):2937-2950.
3. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunnuosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998, 31(5):335-340.
4. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP, Grandaliano G. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005, 352(13):1317-1323.
5. Trinh XB, Tjalma WA, Vermeulen PB, Van den Eynden G, Van der Auwera I, Van Laere SJ, Helleman J, Berns EM, Dirix LY, Van Dam PA. The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br J Cancer 2009, 100(6):971-978.
6. Advani SH. Targeting mTOR pathway: a new concept in cancer therapy. Indian J Med Paediatr Oncol 2010, 31(4):132-136.
7. Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 2011, 121(4):1231-1241.
8. Cen P, Amato RJ. Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus. Onco Targets Ther 2012, 5:217-224.
9. Kwiatkowski DJ. Tuberous sclerosis: from tubers to mTOR. Ann Hum Genet 2003, 67(Pt 1):87-96.
10. Pascual J. Everolimus in clinical practice-renal transplantation. Nephrol Dial Transplant 2006, 21(Suppl 3):iii18-iii23.
11. Pallet N, Legendre C. Adverse events associated with mTOR inhibitors. Expert Opin Drug Saf 2013, 12(2):177-186.
12. Stallone G, Infante B, Grandaliano G, Gesualdo L. Management of side effects of sirolimus therapy. Transplantation 2009, 87(8 Suppl):S23-S26.
13. Porta C, Osanto S, Ravaud A, Climent MA, Vaishampayan U, White DA, Creel P, Dickow B, Fischer P, Gornell SS, Meloni F, Motzer RJ. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 2011, 47(9):1287-1298.
14. Morelon E, Stern M, Israel B, Correas JM, Danel C, Mamzer-Bruneel MF, Peraldi MN, Kreis H. Characteristics of sirolimus associated interstitial pneumonitis in renal transplant patient. Transplantation 2001, 72(5):787-790.
15. Errasti P, Izquierdo D, Martín P, Errasti M, Slon F, Romero A, Lavilla FJ. Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience. Transplant Proc 2010, 42(8):3053-3054.
16. Rodríguez-Moreno A, Ridao N, García-Ledesma P, Calvo N, Pérez-Flores I, Marques M, Barrientos A, Sánchez-Fructuoso AI. Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center. Transplant Proc 2009, 41(6):2163-2165.
17. Alexandru S, Ortiz A, Baldovi S, Milicua JM, Ruíz-Escribano E, Egido J, Plaza JJ. Severe everolimus-associated pneumonitis in a renal transplant recipient. Nephrol Dial Transplant 2008, 23(10):3353-3355.
18. Selman M, Pardo A. Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorder. Respir Res 2002, 3:3.
19. Hodge S, Holmes M, Banerjee B, Musk M, Kicic A, Waterer G, Reynolds PN, Hodge G, Chambers DC. Post-transplant bronchiolitis obliterans syndrome is associated with bronchial epithelial to mesenchymal transition. Am J Transplant 2009, 9(4):727-733.
20. Ward C, Forrest IA, Murphy DM, Johnson GE, Robertson H, Cawston TE. Epithelial to mesenchymal transition in clinically stable lung transplant recipients. J Heart Lung Transpl 2005, 24:S48-S49.
21. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 2002, 110(3):341-350.
22. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 2010, 21(2):212-222.
23. Lan HY. Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells. Curr Opin Nephrol Hypertens 2003, 12(1):25-29.
24. Burns WC, Twigg SM, Forbes JM, Pete J, Tikellis C, Thallas-Bonke V, Thomas MC, Cooper ME, Kantharidis P. Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol 2006, 17(9):2484-2494.
25. Ha H, Lee HB. Reactive oxygen species and matrix remodeling in diabetic kidney. J Am Soc Nephrol 2003, 14(8 Suppl 3):S246-S249.
26. Masola V, Gambaro G, Tibaldi E, Brunati AM, Gastaldello A, D'Angelo A, Onisto M, Lupo A. Heparanase and syndecan-1 interplay orchestrates fibroblast growth factor-2-induced epithelial-mesenchymal transition in renal tubular cells. J Biol Chem 2012, 287(2):1478-1488.
27. Masola V, Gambaro G, Tibaldi E, Onisto M, Abaterusso C, Lupo A. Regulation of heparanase by albumin and advanced glycation end products in proximal tubular cells. Biochim Biophys Acta 2011, 1813(8):1475-1482.
28. Masola V, Onisto M, Zaza G, Lupo A, Gambaro G. A new mechanism of action of sulodexide in diabetic nephropathy: inhibits heparanase-1 and prevents FGF-2-induced renal epithelial-mesenchymal transition. J Transl Med 2012, 10:213.
29. Van den Hoven MJ, Rops AL, Vlodavsky I, Levidiotis V, Berden JH, Van der Vlag J. Heparanase in glomerular diseases. Kidney Int 2007, 72(5):543-548.
30. Rops AL, Van den Hoven MJ, Veldman BA, Salemink S, Vervoort G, Elving LD, Aten J, Wetzels JF, Van der Vlag J, Berden JH. Urinary heparanase activity in patients with type 1 and type 2 diabetes. Nephrol Dial Transplant 2012, 27(7):2853-2861.
31. Shafat I, Agbaria A, Boaz M, Schwartz D, Baruch R, Nakash R, Ilan N, Vlodavsky I, Weinstein T. Elevated urine heparanase levels are associated with proteinuria and decreased renal allograft function. PLoS One 2012, 7(9):e44076.
32. Humphreys BD, Lin SL, Kobayashi A, Hudson TE, Nowlin BT, Bonventre JV, Valerius MT, McMahon AP, Duffield JS. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2010, 176(1):85-97.
33. LeBleu VS, Taduri G, O'Connell J, Teng Y, Cooke VG, Woda C, Sugimoto H, Kalluri R. Origin and function of myofibroblasts in kidney fibrosis. Nat Med 2013, 19(8):1047-1053.
34. Gröger CJ, Grubinger M, Waldhör T, Vierlinger K, Mikulits W. Meta-analysis of gene expression signatures defining the epithelial to mesenchymal transition during cancer progression. PLoS One 2012, 7(12):e51136.
35. Storey JD, Tibshirani R. Statistical significance for genome wide studies. Proc Natl Acad Sci U S A 2003, 100(16):9440-9445.
36. Morales JM, Wramner L, Kreis H, Durand D, Campistol JM, Andres A, Arenas J, Nègre E, Burke JT, Groth CG. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002, 2(5):436-442.
37. Velosa JA, Larson TS, Gloor JM, Stegall MD. Cyclosporine elimination in the presence of TOR inhibitors: effects on renal function, acute rejection, and safety. Am J Kidney Dis 2001, 38(4 Suppl 2):S3-S10.
38. Boulay A, Lane HA. The mammalian target of rapamycin kinase and tumor growth inhibition. Recent Results Cancer Res 2007, 172:99-124.
39. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007, 12(1):9-22.
40. Chiang GC, Abraham RT. Targeting the mTOR signaling network in cancer. Trends Mol Med 2007, 13(10):433-442.
41. Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 2011, 10(11):868-880.
42. Kurdián M, Herrero-Fresneda I, Lloberas N, Gimenez-Bonafe P, Coria V, Grande MT, Boggia J, Malacrida L, Torras J, Arévalo MA, González-Martínez F, López-Novoa JM, Grinyó J, Noboa O. Delayed mTOR inhibition with low dose of everolimus reduces TGFβ expression, attenuates proteinuria and renal damage in the renal mass reduction model. PLoS One 2012, 7(3):e32516.
43. Geissler EK, Schlitt HJ. MTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression. Kidney Int 2011, 79(5):502-511.
44. Pontrelli P, Rossini M, Infante B, Stallone G, Schena A, Loverre A, Ursi M, Verrienti R, Maiorano A, Zaza G, Ranieri E, Gesualdo L, Ditonno P, Bettocchi C, Schena FP, Grandaliano G. Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation 2008, 85(1):125-134.
45. Breuleux M, Klopfenstein M, Stephan C, Doughty CA, Barys L, Maira SM, Kwiatkowski D, Lane HA. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol Cancer Ther 2009, 8(4):742-753.
46. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007, 26(13):1932-1940.
47. Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell 2007, 12(4):487-502.
48. Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res 2012, 18(21):5856-5864.
49. Gilles C, Polette M, Mestdagt M, Nawrocki-Raby B, Ruggeri P, Birembaut P, Foidart JM. Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res 2003, 63(10):2658-2664.
50. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66(3):1500-1508.
51. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005, 65(16):7052-7058.
52. O'Donnell A, Faivre S, Burris HA, Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E, Judson I. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008, 26(10):1588-1595.
53. Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R, Tobler S, Heusser C, O'Reilly T, Stolz B, Marti A, Thomas G, Lane HA. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004, 64(1):252-261.
54. Tanaka C, O'Reilly T, Kovarik JM, Shand N, Hazell K, Judson I, Judson I, Raymond E, Zumstein-Mecker S, Stephan C, Boulay A, Hattenberger M, Thomas G, Lane HA. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 2008, 26(10):1596-1602.
55. Katoh M, Katoh M. Cross-talk of WNT and FGF signaling pathways at GSK3beta to regulate beta-catenin and SNAIL signaling cascades. Cancer Biol Ther 2006, 5(9):1059-1064.
56. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene 2005, 24(50):7443-7454.
57. Masola V, Maran C, Tassone E, Zin A, Rosolen A, Onisto M. Heparanase activity in alveolar and embryonal rhabdomyosarcoma: implications for tumor invasion. BMC Cancer 2009, 9:304.
58. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001, 108(3):341-347.
59. Nasser NJ. Heparanase involvement in physiology and disease. Cell Mol Life Sci 2008, 65(11):1706-1715.
60. Vreys V, David G. Mammalian heparanase: what is the message?. J Cell Mol Med 2007, 11(3):427-452.
61. Szymczak M, Kuzniar J, Klinger M. The role of heparanase in diseases of the glomeruli. Arch Immunol Ther Exp (Warsz) 2010, 58(1):45-56.
62. Whitman M. Smads and early developmental signaling by the TGFbeta superfamily. Genes Dev 1998, 12(16):2445-2462.
63. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res 2009, 19(2):156-172.
64. Wang B, Koh P, Winbanks C, Coughlan MT, McClelland A, Watson A, Jandeleit-Dahm K, Burns WC, Thomas MC, Cooper ME, Kantharidis P. miR-200a Prevents renal fibrogenesis through repression of TGF-β2 expression. Diabetes 2011, 60(1):280-287.
65. Hill C, Flyvbjerg A, Grønbaek H, Petrik J, Hill DJ, Thomas CR, Sheppard MC, Logan A. The renal expression of transforming growth factor-beta isoforms and their receptors in acute and chronic experimental diabetes in rats. Endocrinology 2000, 141(3):1196-1208.
66. Hill C, Flyvbjerg A, Rasch R, Bak M, Logan A. Transforming growth factor-beta2 antibody attenuates fibrosis in the experimental diabetic rat kidney. J Endocrinol 2001, 170(3):647-651.
67. Chen J, Chen JK, Nagai K, Plieth D, Tan M, Lee TC, Threadgill DW, Neilson EG, Harris RC. EGFR signaling promotes TGFβ-dependent renal fibrosis. J Am Soc Nephrol 2012, 23(2):215-224.
68. Xu X, Wan X, Geng J, Li F, Yang T, Dai H. Rapamycin regulates connective tissue growth factor expression of lung epithelial cells via phosphoinositide 3-kinase. Exp Biol Med (Maywood) 2013, 238(9):1082-1094.
69. Zaza G, Tomei P, Ria P, Granata S, Boschiero L, Lupo A. Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors. Clin Dev Immunol 2013, 2013:403280.